Skip to content
ShapeTX
  • About
  • Careers
  • News & Blog
  • Contact

Company News

January 5, 2023

ShapeTX to Showcase Groundbreaking Advances in CNS in vivo RNA Editing, CNS-Targeting AAVs, and TruStableā„¢ AAV Manufacturing at the J.P. Morgan 41st Annual Healthcare Conference

September 12, 2022

Shape Therapeutics named one of Fierce Biotech’s “Fierce 15” Companies of 2022

May 12, 2022

Shape Therapeutics to Present Data Highlighting Advances in Its AI-Driven RNA Technology Platforms at the 2022 ASGCT Annual Meeting

April 26, 2022

Shape Therapeutics Welcomes Google and Stripe Veterans Gayathri Rajan, Kelly Sims to its Board of Directors

January 6, 2022

Shape Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

November 9, 2021

Shape Therapeutics Appoints David J. Huss, Ph. D., as Chief Scientific Officer and Lisa Taylor Ash, J. D., as General Counsel

August 24, 2021

Shape Therapeutics enters into a strategic research collaboration with Roche to advance breakthrough AAV-based RNA editing technology for neuroscience and rare disease indications

July 15, 2021

Shape Therapeutics Secures $112 Million in Series B Financing to Advance Breakthrough RNA Technology Platforms to Democratize Gene Therapy

May 28, 2021

Shape Therapeutics to Present the Discovery of Muscle-Specific AAVs at the Jefferies 2021 Virtual Healthcare Conference

The future of programmable RNA medicine

About Careers News & Blog Contact
Seattle (Headquarters)

219 Terry Avenue North
Seattle, WA 98109

Boston

75 Kneeland Street
Boston, MA 02111

© 2023 Shape TX

© 2023 ShapeTX • Built with GeneratePress

The future of programmable RNA medicine

  • About
  • Careers
  • News & Blog
  • Contact